You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
Vaccine Innovation Forum (VIF) World 2024 to be held in China aims to bring together experts, researchers, policymakers, and industry leaders from around the world to collaborate and advance the field of vaccine development and immunization. Vaccines have played a crucial role in preventing and controlling infectious diseases, and they continue to be instrumental in safeguarding global public health. China, with its significant contributions to vaccine research, development, and production, serves as an ideal host for this prestigious event.
As the world faces emerging infectious threats and ongoing health challenges, it is crucial to foster international cooperation and knowledge exchange in the realm of vaccine development. This conference will serve as a platform to share cutting-edge research findings, discuss innovative vaccine technologies, address global immunization gaps, and promote equitable vaccine distribution.
For more information: pls contact Sam Li sam.li@chstone-events.com, or 86-13482341046
Opening Remark
Next generation nucleic acid approaches for therapeutics / immune therapy of disease and induction of protective immunity
Biomimetic synthetic vaccines: from artificial particles to natural particle chassis
Next generation mucosal vaccine development
Current Vaccine Problem
Introducing Inhalation Vaccine
Some Highlight Result from Clinical and Real World Study
Tea Break
mRNA Vaccine Development: COVID and Beyond
Developing RNA vaccines and therapeutics after COVID-19
Advancing global vaccine R&D franchise for respiratory diseases
Respiratory diseases including low air track infections and related chronical degenerative diseases became leading causes of death globally. Recently, WHO announced the end of the Covid pandemics which lasted over 3 years. SCB-2019 is a protein subunit vaccine with adjuvant against Covid-19. With trials enrolling over 37500 human subjects, SCB-2019 was demonstrated efficacious across various subgroups including adults over 60, adolescence and young adults, either used for primary immunization or as a booster. SCB-2019 can provide protection against pre-omicron and some omicron strains of Covid-19. With EUA of SCB-2019, Clover successfully grew into a full-fledged biopharma with proprietary trimer-tag platform, China-centric discovery and commercial teams, and global development and regulatory capabilities. To meet the need for protection against Covid-19 XBB strains, Clover developed both SCB-2023 including a XBB.1.5 antigen and raced to deliver them before the next wave of pandemics in this year. Along with Covid-19, spread of other respiratory infectious diseases, such as influenza and RSV, also imposed serious threats on human health. Clover in-licensed a Flu vaccine which will hit the market in the 2nd half of this year. Based on trimer-tag and unique stabilizing mutations, RSV vaccine is also under preclinical development with desirable immunogenicity data. Clover is committed to provide comprehensive solutions for vaccination against respiratory diseases.
Networking Lunch
Moderator
Clinical development for the first approved mRNA vaccine in China
Advancing Global Health Through Innovative Vaccine Research and Development: Lessons Learned from Hilleman
Empowering mRNA therapy development with innovative technologies
Decoding adjuvant technologies in recombinant vaccine development
Tea Break
Research and development of kits for vaccine quantification and immunogenicity evaluatio
Challenges and opportunities: Advancing Chinese vaccine products to the global market
Nanoparticulate Delivery of Subunit Antigens and Molecular Adjuvants
The vaccines of subunits, peptides, and mRNA represent new generation of vaccination technology for fighting infectious diseases and cancers. However, these biomacromolecules face the problems of degradation, transportation to target tissue and cells, and cellular uptake, which are the obstacles of their technology translation. Delivery technology based on materials and nanoparticular engineering becomes “last mile” of clinical application of novel vaccines. In this talk, I will present our research on nanovaccines by delivering subunits and adjuvants for eliciting potent humoral and cellular response. We have applied both biocompatible materials and engineered fabricating technologies to improve lymph node targeting and retention, and in turn the performance of the novel nanovaccines, which were evaluated in EV71, EBV and HB associated diseases.
Intranasal Immunization: Device and Formulation Promises and Challenges
End of Day 1
Moderator
Microneedle as a powerful delivery tool for DNA vaccination
Vaccine development and immunology: from Zika to COVID-19
Addressing IP challenges for RNA-based vaccine development
Dan will provide an in-depth discussion relating to the IP, litigation and competitive landscape in the mRNA and lipid nanoparticle space including recent trends and related analyses.
Novel self-assembled RNA nanoparticles for vaccination and therapy
After the successful development of lipid nanoparticles (LNPs) comprising messenger RNA (mRNA) for vaccination against Covid-19 the interest in mRNA and nanoparticle systems for various therapeutic applications has surged tremendously.
As delivery systems, currently LNPs, which are manufactured by a specific protocol with a defined mixture of four lipids are center of attention. However, there are several other nanoparticle formats which have demonstrated to be promising as delivery systems for RNA and other drugs.
Here some concepts for nanoparticle engineering based on lipids and polymers are presented, which allow for tailoring of the delivers system according to type of (RNA) cargo, application route and the intended therapeutic intervention.
Tea Break
Development of polyvalent pneumococcal conjugate vaccine against pneumococcal diseases
Streptococcus pneumoniae is a leading pathogen commonly colonized in human upper respiratory tract. Pneumococcal infection may cause meningitis, bacteremia, pneumonia, and acute otitis media, especially in susceptible populations. Pneumococcal vaccine has been proved as an effective approach to combat the pneumococcal disease. However, due to emerging of new pneumococcus serotypes and diverse epidemiology across the world, development of more effective vaccines to provide a much wider protection becomes necessary. In this presentation, I will give a summary on the development progress of polyvalent pneumococcal conjugate vaccines worldwide.
Russia& CIS: vaccine market highlights & entry models
Russia&CIS vaccine markets:dynamics and structure
Overall pharma trends in Russia and development of governmental support
Vaccine market regulatory background
Market entry models and cooperation opportunities
Nanolek as a potential partner
Networking Lunch
Moderator
Convacell – second generation vaccine against COVID-19
Plant-based vaccine development
Baiya Phytopharm, company introduction
Baiya pharming process, Plant-based vaccine, and therapeutic protein.
Baiya’s plant-based Covid-19 vaccine development during the pandemic.
Future for Plant-based technology platform.
Targeted LNP in cancer vaccine development
Structure-based vaccine development
Challenges and opportunities for novel mRNA therapy development
Panel discussion: The future of vaccine development
Opening Remark
Next generation nucleic acid approaches for therapeutics / immune therapy of disease and induction of protective immunity
Biomimetic synthetic vaccines: from artificial particles to natural particle chassis
Next generation mucosal vaccine development
Tea Break
mRNA Vaccine Development: COVID and Beyond
Developing RNA vaccines and therapeutics after COVID-19
Advancing global vaccine R&D franchise for respiratory diseases
Networking Lunch
Moderator
Clinical development for the first approved mRNA vaccine in China
Advancing Global Health Through Innovative Vaccine Research and Development: Lessons Learned from Hilleman
Empowering mRNA therapy development with innovative technologies
Decoding adjuvant technologies in recombinant vaccine development
Tea Break
Research and development of kits for vaccine quantification and immunogenicity evaluatio
Challenges and opportunities: Advancing Chinese vaccine products to the global market
Nanoparticulate Delivery of Subunit Antigens and Molecular Adjuvants
Intranasal Immunization: Device and Formulation Promises and Challenges
End of Day 1
Moderator
Microneedle as a powerful delivery tool for DNA vaccination
Vaccine development and immunology: from Zika to COVID-19
Addressing IP challenges for RNA-based vaccine development
Novel self-assembled RNA nanoparticles for vaccination and therapy
Tea Break
Development of polyvalent pneumococcal conjugate vaccine against pneumococcal diseases
Russia& CIS: vaccine market highlights & entry models
Networking Lunch
Moderator
Convacell – second generation vaccine against COVID-19
Plant-based vaccine development
Targeted LNP in cancer vaccine development
Structure-based vaccine development
Challenges and opportunities for novel mRNA therapy development
Panel discussion: The future of vaccine development
Fenda International Hotel Beijing
北京丰大国际大酒店
NO. 20, Middle Ronghua Rd, Daxing District, Beijing China
北京市大兴区荣华中路20号
Tel: 86-10-67518888
Refund Description:No Refund
pls kindly notice that refund will not be available, you could arrange other colleagues to join if you cannot show.